annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 14H Median time to progression in chemotherapy (chemo)-naive patients with
castration-resistant prostate cancer (CRPC) treated with abiraterone acetate
and low-dose prednisone (Pred). (Abstract #4671)
C. J. Ryan, M. R. Smith, C. Logothetis, K. Koepfgen, M. Taplin, A. L. Harzstark,
P. Kantoff, T. S. Kheoh, A. Molina, E. J. Small
Brd. 15A Durable disease control, safety, and tolerability of abiraterone acetate (AA) in
advanced castration-resistant prostate cancer (CRPC). (Abstract #4672)
D. Bianchini.
Brd. 15B Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa)
patients switched from leuprolide to degarelix or receiving continuous
degarelix treatment. (Abstract #4673)
N. D. Shore, J. W. Moul, E. Crawford, T. Olesen, B. Persson
Brd. 15C HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate
resistant prostate cancer (CRPC): Results of phase I/II clinical trial.
(Abstract #4674)
R. B. Montgomery, M. J. Morris, C. J. Ryan, D. R. Stickney, J. M. Frincke,
C. L. Reading, J. Sarantopoulos, H. I. Scher
Brd. 15D Association of ADT for older men with biochemical recurrence of prostate
cancer with obese frailty and falls: A case-control study. (Abstract #4675)
W. Dale, K. A. Bylow, J. Hemmerich, S. G. Mohile, S. Sajid, W. M. Stadler
Brd. 15E Effect of toremifene on fracture risk in men younger than age 80 on
androgen-deprivation therapy. (Abstract #4676)
M. K. Brawer, M. R. Smith, S. B. Malkowicz, M. L. Hancock, R. A. Morton,
M. S. Steiner
Brd. 15F Initial feasibility and safety results from a phase II/III clinical trial to evaluate
docetaxel (D) therapy in combination with zoledronic acid (ZA) �/- strontium-
89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.
(Abstract #4677)
E. Porfiri, S. I. Collins, D. Barton, L. Billingham, D. McLaren, G. G. Nixon,
J. M. Russell, C. Parker, J. Wylie, N. D. James, Trapeze Phase II
Brd. 15G Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign
safety profile for patients with castration-resistant prostate cancer (CRPC)
and bone metastases: Combined analysis of phase I and II clinical trials.
(Abstract #4678)
S. Nilsson, C. Parker, I. Haugen, A. Lokna, A. Aksnes, B. Bolstad, G. O’Bryan-
Tear, O. S. Bruland
Brd. 15H Analysis of the cost-effectiveness of zoledronic acid for the prevention
of skeletal-related events in patients with prostate cancer and bone
metastases: A comparison across four European countries. (Abstract #4679)
M. Botteman, F. Logman, S. Kaura
Brd. 16A Phase I pharmacokinetic (PK) and biodistribution study of radium-223
chloride in patients with castration resistant prostate cancer (CRPC)
metastatic to bone. (Abstract #4680)
J. A. Carrasquillo, J. A. O’ Donoghue, N. Pandit-Taskar, D. E. Rathkopf, A. Aksnes,
C. L. Viner, C. T. Hong, S. M. Larson, H. I. Scher, M. J. Morris
Brd. 16B Safety results of a phase III trial evaluating ADT� docetaxel versus ADT
alone in hormone-naive metastatic prostate cancer patients (GETUG-AFU
15/0403). (Abstract #4681)
I. Latorzeff, B. Esterni, M. Habibian, G. Delplanque, C. Theodore, M. Baciuchka,
J. Dauba, B. Laguerre, I. Krakowski, G. Gravis
Brd. 16C Carboplatin plus weekly docetaxel as second-line chemotherapy in
docetaxel-resistant and castration-resistant prostate cancer (CRPC).
(Abstract #4682)
C. W. Reuter, V. Gruenwald, P. Ivanyi, M. A. Morgan, M. Fenner, A. Ganser
367
MONDAY